Granules to tighten oversight after US FDA warning as revenue dependence on US looms

US accounts for most sales, and the FDA flagged gaps

Drugmaker Granules says it will tighten internal oversight following a warning from the US FDA. The company, one of the world’s biggest paracetamol makers and a key active pharmaceutical ingredients player, earns a large share of revenue from the United States—making compliance scrutiny especially consequential for future supply and sales.